IKT — Inhibikase Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual balance sheet for Inhibikase Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash
Short Term Investments
Cash and Short Term Investments	40.8	23.1	13.3	97.5	179
Net Total Accounts Receivable
Net Total Receivables	0.11	0.04	0	—	—
Prepaid Expenses
Total Current Assets	42.5	24.4	14.2	98.5	180
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	—	0.565	0.296	0.149	0
Other Long Term Assets
Total Assets	42.5	24.9	14.5	98.6	181
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	4.05	3.7	3.44	3.73	8.3
Long Term Debt
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	4.05	3.9	3.53	3.73	8.3
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	38.4	21	11	94.9	173
Total Liabilities & Shareholders' Equity	42.5	24.9	14.5	98.6	181
Total Common Shares Outstanding